Fish vaccine maker Pharmaq saw revenues and profits nudge up last year on the back of an improved position in the vaccine and lice treatment markets.
Turnover improved from NOK 440.7 million (€54.1 million/$73.6 million) in 2012 to NOK 448.3 million (€55 million/$74.8 million) in 2013, while operating profit last year came to NOK 104.1 million (€12.8 million/$17.4 million), as opposed to NOK 103.1 million (€12.7 million/$17.2 million) the previous year.
Pharmaq’s Board of Directors wrote in the annual report: “The main explanation for the improvement in revenue is a stronger position in the Norwegian vaccine market and increased revenue from lice treatments.”
In
